Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 17 · below the Ichimoku cloud · RSI 23 (oversold) · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $641.7K | 0.00% | 20.41K | −53% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NGNE trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 6, 2026 | Cvijic Christine MikailPresident | Sale at price 36.02 - 36.13 per share. | 4.8K | $173.38K |
| Jul 1, 2026 | Cvijic Christine MikailPresident | Sale at price 34.06 - 35.23 per share. | 4.8K | $166.59K |
| May 5, 2026 | Cvijic Christine MikailPresident | Sale at price 30.07 - 32.44 per share. | 9.6K | $300.04K |
| Mar 25, 2026 | Cvijic Christine MikailPresident | Sale at price 21.62 per share. | 2.6K | $55.32K |
| Mar 25, 2026 | Mcminn Rachel L.Chief Executive Officer | Sale at price 22.07 per share. | 3.4K | $74.00K |
| Mar 25, 2026 | Jordan JulieOfficer | Sale at price 21.89 per share. | 828 | $18.13K |
| Mar 12, 2026 | Cvijic Christine MikailPresident | Sale at price 20.42 - 22.02 per share. | 4K | $84.18K |
| Mar 12, 2026 | Cobb StuartOfficer | Sale at price 20.41 - 22.08 per share. | 6.8K | $141.45K |
| Feb 26, 2026 | Cvijic Christine MikailChief Executive Officer | Sale at price 25.11 per share. | 4.8K | $120.53K |
| Feb 19, 2026 | Cvijic Christine MikailPresident | Stock Award(Grant) at price 0.00 per share. | 22K | — |
| Feb 19, 2026 | Mcminn Rachel L.Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 25.9K | — |
| Feb 19, 2026 | Jordan JulieOfficer | Stock Award(Grant) at price 0.00 per share. | 4.9K | — |
| Feb 19, 2026 | Cobb StuartOfficer | Stock Award(Grant) at price 0.00 per share. | 16.5K | — |
| May 13, 2025 | Cobb StuartOfficer | Sale at price 15.15 per share. | 6.8K | $103.00K |
| Mar 25, 2025 | Cvijic Christine MikailPresident | Stock Award(Grant) at price 0.00 per share. | 20.3K | — |
| Mar 25, 2025 | Mcminn Rachel L.Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 23.9K | — |
| Mar 25, 2025 | Jordan JulieOfficer | Stock Award(Grant) at price 0.00 per share. | 8.4K | — |
| Mar 25, 2025 | Cobb StuartOfficer | Stock Award(Grant) at price 0.00 per share. | 7.2K | — |
| Mar 12, 2025 | Cvijic Christine MikailPresident | Sale at price 16.94 per share. | 4.5K | $76.25K |
| Nov 25, 2024 | Samsara Biocapital Gp, LlcBeneficial Owner of more than 10% of a Class of Security | Purchase at price 24.91 - 27.50 per share. | 48.8K | $1.26M |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.3 | 33.0 | -14.2 | 29.4 | 8.6 | 11.0 | 4.6 | 10.2 | -23.2 | -20.3 | +7.7% | ||
| 2025 | -30.7 | 11.6 | -33.8 | 28.1 | 13.4 | -12.1 | 45.6 | -15.1 | -6.2 | 97.7 | -38.5 | -2.3 | −9.9% |
| 2024 | 55.6 | 3.0 | 63.8 | -32.3 | 9.0 | -3.2 | 13.1 | -9.0 | 12.1 | 4.9 | -42.2 | -10.1 | +18.0% |
| 2023 | 16.9 | -15.5 | 39.2 | 27.7 | -10.5 | 3.8 | -16.9 | 9.1 | 4.9 | -14.4 | 2.4 | 40.0 | +90.4% |
| 2022 | -25.9 | -27.7 | -27.1 | -35.1 | -18.0 | 3.0 | -1.9 | 2.0 | -37.9 | -11.3 | -10.2 | -0.2 | −89.4% |
| 2021 | -10.6 | -4.4 | 2.2 | 1.5 | -19.7 | -8.0 | -24.3 | 16.6 | -11.3 | 1.4 | -26.9 | -10.1 | −65.8% |
| 2020 | 0.3 | -21.5 | 17.3 | -2.1 | 9.3 | 36.3 | -41.7 | 31.3 | -5.6 | -12.6 | 21.0 | 11.1 | +14.4% |
| 2019 | 6.5 | 14.8 | 2.1 | -0.9 | -2.2 | -9.6 | 13.1 | 25.1 | -14.7 | 4.6 | 87.2 | 120.8 | +470.4% |
| 2018 | 9.9 | 12.1 | -2.8 | -13.4 | 17.6 | -81.5 | 11.7 | 5.4 | -6.1 | -11.9 | -8.1 | -8.9 | −81.6% |
| 2017 | 9.4 | -4.3 | -3.4 | -12.0 | -13.1 | 10.3 | 0.5 | 3.3 | -2.9 | -20.6 | -6.3 | 11.4 | −28.8% |
| 2016 | -15.9 | -15.3 | -0.8 | -7.7 | 1.1 | -19.6 | 26.1 | 27.2 | 25.8 | -21.6 | 33.0 | 18.5 | +32.3% |
| 2015 | 41.5 | -8.1 | -15.7 | -17.8 | 16.8 | -12.1 | -73.5 | 829.9 | -17.8 | 8.7 | -21.6 | 4.1 | +66.4% |
| 2014 | -28.3 | -2.6 | 6.1 | -17.9 | 6.1 | -18.9 | -0.5 | 10.3 | 2.6 | −41.1% |
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Buy / hold / sell counts